Cann Group (CHIA:CAN) - Stock Price, News & Analysis

CAN Stock Overview

Engages in the breeding, cultivating, manufacturing, and selling medicinal cannabis in Australia and Europe.

CAN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

Rewards

Risk Analysis

Earnings have declined by 23.8% per year over past 5 years

Highly volatile share price over the past 3 months compared to the Australian market

Shareholders have been diluted in the past year

Does not have a meaningful market cap (A$22M)

Cann Group Limited Competitors

Althea Group Holdings

ASX:AGH

AU$23.4m

Nyrada

ASX:NYR

AU$21.0m

Rhinomed

ASX:RNO

AU$11.5m

Invion

ASX:IVX

AU$13.5m

Price History & Performance

Summary of all time highs, changes and price drops for Cann Group
Historical stock prices
Current Share Price	AU$0.045
52 Week High	AU$0.15
52 Week Low	AU$0.027
Beta	1.09
11 Month Change	-25.00%
3 Month Change	28.57%
1 Year Change	-62.50%
33 Year Change	-84.48%
5 Year Change	-95.63%
Change since IPO	-93.08%

Recent updates

Shareholder Returns

	CAN	AU Pharmaceuticals	AU Market
7D	9.8%	3.4%	0.2%
1Y	-62.5%	64.3%	16.6%

Return vs Industry: CAN underperformed the Australian Pharmaceuticals industry which returned 59.4% over the past year.

Return vs Market: CAN underperformed the Australian Market which returned 16.2% over the past year.

Price Volatility

Is CAN's price volatile compared to industry and market?
CAN volatility
CAN Average Weekly Movement	23.8%
Pharmaceuticals Industry Average Movement	12.0%
Market Average Movement	8.4%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.5%

Stable Share Price: CAN's share price has been volatile over the past 3 months compared to the Australian market.

Volatility Over Time: CAN's weekly volatility has increased from 17% to 24% over the past year.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Jenni Pilcher	www.canngrouplimited.com

Cann Group Limited, together with its subsidiaries, engages in the breeding, cultivating, manufacturing, and selling medicinal cannabis in Australia and Europe. It also licenses to undertake research and to cultivate cannabis for human medicinal and research purposes. The company was founded in 2014 and is based in Port Melbourne, Australia.

Cann Group Limited Fundamentals Summary

How do Cann Group's earnings and revenue compare to its market cap?
CAN fundamental statistics
Market cap	AU$22.04m
Earnings (TTM)	-AU$51.24m
Revenue (TTM)	AU$18.36m

1.2x

P/S Ratio

-0.4x

P/E Ratio

Is CAN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CAN income statement (TTM)
Revenue	AU$18.36m
Cost of Revenue	AU$12.18m
Gross Profit	AU$6.18m
Other Expenses	AU$57.42m
Earnings	-AU$51.24m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.11
Gross Margin	33.66%
Net Profit Margin	-279.13%
Debt/Equity Ratio	516.6%

How did CAN perform over the long term?

See historical performance and comparison

CAN Stock Overview

Rewards

Risk Analysis

Cann Group Limited Competitors

ASX:AGH

AU$23.4m

ASX:NYR

AU$21.0m

ASX:RNO

AU$11.5m

ASX:IVX

AU$13.5m

Price History & Performance

Recent News & Updates

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

Recent updates

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 6.252486 million.

Cann Group Limited, Annual General Meeting, Oct 28, 2024

Full year 2024 earnings released: AU$0.12 loss per share (vs AU$0.091 loss in FY 2023)

Cann Group Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Cann Group Limited Appoints Jenni Pilcher as Managing Director

Less than half of directors are independent

New major risk - Financial position

Cann Group Limited Appoints Tony Di Pietro as Joint Company Secretary of Head of Legal and Regulatory Affairs

Cann Group Limited Announces Resignation of Deborah Ambrosini as Chief Financial Officer, Effective December 22, 2023

Cann Group Limited has filed a Follow-on Equity Offering in the amount of AUD 0.3756 million.

Cann Group Limited, Annual General Meeting, Oct 26, 2023

Full year 2023 earnings released: AU$0.091 loss per share (vs AU$0.079 loss in FY 2022)

New minor risk - Financial data availability

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 11.658446 million.

Cann Group Limited Provides Revenue Guidance for the Year Ended June 30, 2023

New minor risk - Share price stability

First half 2023 earnings released: AU$0.053 loss per share (vs AU$0.028 loss in 1H 2022)

Cann Group Limited Announces Preliminary Results from Their Phase 3 Clinical Trail

Cann Group Limited Announces Chief Executive Officer Changes

Cann Group Limited Announces Final Clinical Trial Participant Completes Study

Less than half of directors are independent

Cann Group Limited Appoints Julian John Chick as Director

Cann Group Limited Announces Resignation of Peter Crock as CEO

Cann Group Limited Meets its Enrolment Target for Phase III Clinical Trial of Low-Dose Satipharm CBD Capsules for Short-Term Sleep Disturbance

Cann Group Limited Announces Executive Changes

Cann Group Limited Appoints Robert Barnes & Julian Chick to the Board

Cann Group Limited Announces Resignation of John Sharman as Director

Cann Group Limited, Annual General Meeting, Oct 25, 2022

Full year 2022 earnings released: AU$0.079 loss per share (vs AU$0.098 loss in FY 2021)

Cann Group Limited Announce Therapeutic Goods Administration Grants Cann GMP License to Manufacture Therapeutic Goods

Cann Group Limited Receives Second Payment from Victorian Government's Regional Jobs Fund Program

Less than half of directors are independent

Office of Drug Control Grants Permit for Manufacture of Medicinal Cannabis Products to Cann Group Limited

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Cann Group Limited Announces Resignation of Mr. Geoffrey Pearce as Non-Executive Director

Cann Group Limited Announces Cann to Begin Recruitment for CBD Phase 3 Clinical Trial

Rua Bioscience Limited (NZSE:RUA) agreed to acquire 8.36% stake in Zalm Therapeutics Ltd from Cann Group Limited (ASX:CAN) for NZD 10 million.

Chief Financial Officer Greg Bullock has left the company

Full year 2021 earnings released: AU$0.097 loss per share (vs AU$0.12 loss in FY 2020)

Cann Group Limited Revises Revenue Guidance for the Year 2021

Cann Group Limited (ASX:CAN) completed the acquisition of Satipharm Ltd, Satipharm AG and Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT)

Cann Group Limited, Olivia Newton-John Cancer Research Institute and Austin Health Partnered in A Clinical Tria to Assess Medicinal Cannabis for Symptom Management in People with Advanced Cancer

Cann Group Limited (ASX:CAN) entered into a definitive sale agreement to acquire Phytotech Therapeutics Ltd from Harvest One Cannabis Inc. (TSXV:HVT).

First half 2021 earnings released: AU$0.05 loss per share (vs AU$0.06 loss in 1H 2020)

Cann Group Limited (ASX:CAN) signed a share sale agreement to acquire Satipharm Ltd from Harvest One Cannabis Inc. (TSXV:HVT) for CAD 4 million.

New 90-day high: AU$0.76

Australis Capital Inc. and Cann Group Limited Sign Agreement

Cann Group Limited Receives Initial 19,000 Unit Order for Europe

New 90-day high: AU$0.49

Deputy Chairman recently bought AU$55k worth of stock

An unknown buyers acquired 11.84% stake in Cann Group Limited (ASX:CAN) from Aurora Cannabis Inc. (TSX:ACB).

New 90-day low: AU$0.39

Cann Group Limited(ASX:CAN) dropped from S&P Global BMI Index

Deputy Chairman recently bought AU$79k worth of stock

Full year earnings released - AU$0.12 loss per share

New 90-day low - AU$0.44

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 25.9 million.

New 90-day low - AU$0.46

Cann Group Limited has completed a Follow-on Equity Offering in the amount of AUD 14.3 million.